Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Istituti Ospitalieri di Cremona
- Target Recruit Count
- 1
- Registration Number
- NCT02616848
- Locations
- 🇮🇹
AO Cremona, Cremona, Lombardia, Italy
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 263
- Registration Number
- NCT02599324
- Locations
- 🇺🇸
Whittingham Cancer Center at Norwalk Hospital /ID# 1128-0411, Norwalk, Connecticut, United States
🇬🇧Sarah Cannon Research Institute /ID# 1128-1079, London, England, United Kingdom
🇺🇸Franciscan Health Indianapolis /ID# 1128-1125, Indianapolis, Indiana, United States
Study of the Combination of CM082 With Everolimus in Patients With mRCC
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- AnewPharma
- Target Recruit Count
- 18
- Registration Number
- NCT02577458
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Jochen Roessler
- Registration Number
- NCT02569125
- Locations
- 🇩🇪
Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪Vivantes Klinikum Neukölln, Berlin, Germany
🇩🇪Universitätsklinikum Leipzig, Leipzig, Germany
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-10-12
- Target Recruit Count
- 4
- Registration Number
- NCT02560012
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT02539459
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- amy tiersten
- Target Recruit Count
- 62
- Registration Number
- NCT02531932
- Locations
- 🇺🇸
Mount Sinai Downtown, New York, New York, United States
🇺🇸Mount Sinai West, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 15
- Registration Number
- NCT02520063
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 110
- Registration Number
- NCT02511639
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, AN, Italy
🇮🇹ASL Brindisi "Antonio Perrini", Brindisi, BR, Italy
🇮🇹Ospedale Papa Giovanni XXIII, Bergamo, Bg, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.